Inacelli Queiroz de Souza Caires
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Inacelli Queiroz de Souza Caires has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ana M. Mencarini
Universidade de São Paulo
1 shared publication - Bruno Mendonça Protásio
Programa de Pós-Graduação em Oncologia, Faculdade de Medicina da Universidade de São Paulo- FMUSP, Sao Paulo, Brazil; Núcleo de Oncologia da Bahia- NOB. Grupo Oncoclínicas, Salvador, Brazil
1 shared publication - Henrique F. Braga
Universidade de São Paulo
1 shared publication - Iuri A. Santana
Universidade de São Paulo
1 shared publication Julia Andrade de Oliveira
Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo - ICESP/Faculdade de Medicina do Estado de São Paulo - HC/FMUSP, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, CEP: 01246-000, Brazil
1 shared publication- Julia Andrade de Oliveira
Divisionof Medical Oncology, Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina, Universidade de São Paulo, Av. Dr. Arnaldo 251, 5º andar, São Paulo, SP, 01246-000, Brazil,
1 shared publication
Latest Publications
- 1 September 2015
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 192, 86-89
Definitive chemoradiotherapy for advanced cervical cancer: should it be different in the elderly?
- 1 September 2015
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 192, 86-89
Definitive chemoradiotherapy for advanced cervical cancer: should it be different in the elderly?
- 2 August 2014
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 120 (2) , 399-403
Antiepileptic drug prophylaxis in primary brain tumor patients: is current practice in agreement to the consensus?
The role of antiepileptic drugs (AED) prophylaxis in primary brain tumor (PBT) seizure-naïve patients remains unclear. Additionally, AED are associated with severe side effects, negative impact on cognition and drug interactions. Little is known about current practice regarding prophylactic AED use in PBT. We investigated its use in a tertiary care cancer center. We reviewed medical records of 260 patients registered in our center between 2008 and 2012, focusing on prophylactic AED use. A descriptive analysis was performed with SPSS IBM version 20.0. Median age was 44.5 years (11–83). Most patients had ECOG PS ≤1 (76.4 %). Among 141 seizure-naïve patients, 70.2 % received an AED as primary prophylaxis (PP). Most commonly used drugs as PP were phenytoin (85.9 %), carbamazepine (6.1 %) and phenobarbital (5.1 %). In only 14 patients (14.1 %) AEDs were eventually discontinued, in a median time of 5.9 months (1.1–76.8 m). AED were used as PP in 60 % of low-grade gliomas, 73.3 % of anaplastic gliomas and 93.9 % of glioblastoma patients. Twenty-seven patients (27.3 %) on PP presented seizures, generally associated with tumor progression. Of the 42 seizure-naïve patients not receiving AED prophylaxis, only two presented seizures, which occurred during or within the first week post-radiotherapy. In this cross-sectional study, prophylactic AED use in PBT was extremely high. Postoperatively, AED were discontinued in a minority of patients, mostly after a prolonged period. Current prophylactic AED use patterns in PBT are not in accordance with established guidelines.
- 2 August 2014
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 120 (2) , 399-403
Antiepileptic drug prophylaxis in primary brain tumor patients: is current practice in agreement to the consensus?
The role of antiepileptic drugs (AED) prophylaxis in primary brain tumor (PBT) seizure-naïve patients remains unclear. Additionally, AED are associated with severe side effects, negative impact on cognition and drug interactions. Little is known about current practice regarding prophylactic AED use in PBT. We investigated its use in a tertiary care cancer center. We reviewed medical records of 260 patients registered in our center between 2008 and 2012, focusing on prophylactic AED use. A descriptive analysis was performed with SPSS IBM version 20.0. Median age was 44.5 years (11–83). Most patients had ECOG PS ≤1 (76.4 %). Among 141 seizure-naïve patients, 70.2 % received an AED as primary prophylaxis (PP). Most commonly used drugs as PP were phenytoin (85.9 %), carbamazepine (6.1 %) and phenobarbital (5.1 %). In only 14 patients (14.1 %) AEDs were eventually discontinued, in a median time of 5.9 months (1.1–76.8 m). AED were used as PP in 60 % of low-grade gliomas, 73.3 % of anaplastic gliomas and 93.9 % of glioblastoma patients. Twenty-seven patients (27.3 %) on PP presented seizures, generally associated with tumor progression. Of the 42 seizure-naïve patients not receiving AED prophylaxis, only two presented seizures, which occurred during or within the first week post-radiotherapy. In this cross-sectional study, prophylactic AED use in PBT was extremely high. Postoperatively, AED were discontinued in a minority of patients, mostly after a prolonged period. Current prophylactic AED use patterns in PBT are not in accordance with established guidelines.